Literature DB >> 29229601

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Arabella Young1,2, Shin Foong Ngiow1,2,3, Yulong Gao1,2, Ann-Marie Patch4, Deborah S Barkauskas1, Meriem Messaoudene5, Gene Lin6, Jerome D Coudert7, Kimberley A Stannard1, Laurence Zitvogel5,8,9, Mariapia A Degli-Esposti7, Eric Vivier10, Nicola Waddell4, Joel Linden6, Nicholas D Huntington11,12, Fernando Souza-Fonseca-Guimaraes11,12, Mark J Smyth13,2.   

Abstract

Extracellular adenosine is a key immunosuppressive metabolite that restricts activation of cytotoxic lymphocytes and impairs antitumor immune responses. Here, we show that engagement of A2A adenosine receptor (A2AR) acts as a checkpoint that limits the maturation of natural killer (NK) cells. Both global and NK-cell-specific conditional deletion of A2AR enhanced proportions of terminally mature NK cells at homeostasis, following reconstitution, and in the tumor microenvironment. Notably, A2AR-deficient, terminally mature NK cells retained proliferative capacity and exhibited heightened reconstitution in competitive transfer assays. Moreover, targeting A2AR specifically on NK cells also improved tumor control and delayed tumor initiation. Taken together, our results establish A2AR-mediated adenosine signaling as an intrinsic negative regulator of NK-cell maturation and antitumor immune responses. On the basis of these findings, we propose that administering A2AR antagonists concurrently with NK cell-based therapies may heighten therapeutic benefits by augmenting NK cell-mediated antitumor immunity.Significance: Ablating adenosine signaling is found to promote natural killer cell maturation and antitumor immunity and reduce tumor growth. Cancer Res; 78(4); 1003-16. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29229601     DOI: 10.1158/0008-5472.CAN-17-2826

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

Review 1.  Regulation of tumor infiltrated innate immune cells by adenosine.

Authors:  Regina Strakhova; Octavia Cadassou; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2020-06-12       Impact factor: 3.765

2.  Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Authors:  J H Azambuja; R S Schuh; L R Michels; I C Iser; L R Beckenkamp; G G Roliano; G S Lenz; J N Scholl; J Sévigny; M R Wink; M A Stefani; A M O Battastini; F Figueiró; H F Teixeira; E Braganhol
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

Review 3.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 4.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

Review 5.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

Review 6.  The cancer-natural killer cell immunity cycle.

Authors:  Nicholas D Huntington; Joseph Cursons; Jai Rautela
Journal:  Nat Rev Cancer       Date:  2020-06-24       Impact factor: 60.716

7.  Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Authors:  Heidi Harjunpää; Stephen J Blake; Elizabeth Ahern; Stacey Allen; Jing Liu; Juming Yan; Viviana Lutzky; Kazuyoshi Takeda; Amy Roman Aguilera; Camille Guillerey; Deepak Mittal; Xian Yang Li; William C Dougall; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

Review 8.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

9.  Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.

Authors:  Kyohei Nakamura; Mika Casey; Harald Oey; Frank Vari; John Stagg; Maher K Gandhi; Mark J Smyth
Journal:  Leukemia       Date:  2020-04-08       Impact factor: 11.528

Review 10.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.